Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
15 Results for "
type I interferon signaling pathway
" in MedChemExpress (MCE) Product Catalog:
Products (15)
15 Results for "type I interferon signaling pathway" in MCE Product Catalog:
8
8 Publications Verification
Cat. No.: HY-P1934
CAS No.: 14705-60-3
Synonyms: Cyclo(phenylalanylprolyl); A-64863
Research Areas:
3
Target:
Research Areas:
CL075 (3M002) is a selective TLR8 agonist with immunomodulating properties. CL075 triggers a MyD88-dependent signaling pathway to elicit production of inflammatory cytokines and type I interferons (IFNs) via activation of NF-κB and IRF7, respectively .
1
1 Cited Publications
Research Areas:
ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .
1
Dazostinag disodium (TAK-676) is an agonist of STING, triggering the activation of STING signaling pathway and type I interferons. Dazostinag disodium is also a modulator of immune system, resulting complete regressions and durable memory T-cell immunity. Dazostinag disodium promotes durable IFN-dependent antitumor immunity .
1
1 Cited Publications
Cat. No.: HY-150741C
Purity: 97.92%
Target:
Research Areas:
ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 sodium interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus .
1
1 Cited Publications
Cat. No.: HY-160406
CAS No.: 2332803-84-4
Target:
Research Areas:
SNX281 is a selective STING agonist, with IC50 values of 4.1, 4.5, 10.7, and 3.7 μM against human, mouse, rat, and monkey STING, respectively. SNX281 undergoes homodimerization at the STING binding site, triggering a conformational shift of STING from an inactive open state to an active closed state, thereby driving downstream STING-dependent signaling pathways. SNX281 induces type I interferons, IFN-β, TNF-α, IL-6, cytokine release, T cell responses, and long-lasting immune memory. SNX281 exhibits anti-tumor activity and is applicable to research related to colorectal cancer, melanoma, advanced solid tumors, lymphoma, and ovarian cancer .
Cat. No.: HY-164919
CAS No.: 2847102-44-5
Synonyms: XMT-2056
Research Areas:
Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate (ADC) targeting HER2, linked to a payload composed of XMT-1519 conjugate-1 (HY-148067) and STING agonist-20 (HY-148068). Calotatug ginistinag activates the STING signaling pathway in tumor cells and tumor-resident immune cells, induces the production of type I interferons and cytokines (CXCL10, IFN-β, IL-6, TNF-α, triggers innate anti-tumor immune responses, and exerts a bystander effect. Calotatug ginistinag exhibits efficacy against HER2-expressing cancer cells in co-culture with PBMCs. Calotatug ginistinag induces tumor regression and reduces systemic inflammation in various tumor models. Combination treatment with Calotatug ginistinag, Trastuzumab (HY-P9907) and T-DXd (HY-138298) yields benefits. Calotatug ginistinag can be used in studies related to HER2-expressing solid tumors such as breast cancer, gastric cancer and ovarian cancer .
Cat. No.: HY-P9990
CAS No.: 2407378-48-5
Synonyms: BIIB059
Research Areas:
Target:
Research Areas:
GT-653 is a selective KDM5B PROTAC degrader. GT-653 induces ubiquitination and degradation of KDM5B without altering the transcriptional level of KDM5B. GT-653 upregulates the level of H3K4me3. GT-653 activates the type I Interferon signaling pathway. GT-653 can be used for the research of prostate cancer .
Cat. No.: HY-105067A
CAS No.: 922174-60-5
Synonyms: GV-1001 hydrochloride
Research Areas:
Infection Neurological Disease Inflammation/Immunology Cancer
Tertomotide hydrochloride (GV-1001 hydrochloride) is a 16-amino acid peptide derived from hTERT, with both cell-penetrating and immunostimulatory activities, and it can cross the blood-brain barrier. Tertomotide hydrochloride binds to STING, HO-1, eHSP70, eHSP90, bradykinin receptor 1, VEGFR-2, NF-κB, p38 MAPK and Smad2. Tertomotide hydrochloride induces type I interferon production, mitochondrial DNA stress and T-cell responses; inhibits HBV replication, angiogenesis, TGF-β signaling pathway, NF-κB activation, endothelial-mesenchymal transition (EndMT) and fibrosis; regulates microglia; and exerts neuroprotective, anti-inflammatory, antioxidant, anti-apoptotic and anti-tumor effects. Tertomotide hydrochloride can be used in research related to hepatitis B virus infection, Alzheimer's disease, non-small cell lung cancer, atherosclerosis and depression .
Cat. No.: HY-181603
Target:
Research Areas:
Antiviral agent 79 is a broad-spectrum antiviral agent. Antiviral agent 79 exhibits anti-EV71, anti-CVB3 and anti-ADV7 activities. Antiviral agent 79 activates the host type I interferon signaling pathway to enhance antiviral defense. Antiviral agent 79 can be used in research related to viral infections .
Cat. No.: HY-W682115
CAS No.: 30811-80-4
Synonyms: Polycytidylic acid
Research Areas:
Poly(C) (Polycytidylic acid) is a pleiotropic immunostimulant that specifically binds to TLR3, RIG-I and MDA5 receptors. Poly (C) recruits adaptor proteins to activate downstream signaling pathways and induce the production of type I interferons and inflammatory cytokines. Poly (C) triggers cancer cell apoptosis via the intrinsic or extrinsic caspase pathway, thereby exerting inhibitory effects on tumor growth and metastasis. Poly (C) acts as a vaccine adjuvant to modify the tumor microenvironment, regulate the expression of endothelial adhesion molecules and induce virus-like immune responses. Poly (C) can be applied to research related to melanoma, various solid tumors, hematological malignancies and autoimmune insulin-dependent diabetes mellitus .
Cat. No.: HY-L237
338 compounds
Pattern Recognition Receptors (PRRs) are a crucial class of protein molecules expressed in cells of the innate immune system. The core function of Pattern Recognition Receptors is to recognize Pathogen-Associated Molecular Patterns (PAMPs) and Damage-Associated Molecular Patterns (DAMPs). Upon recognizing and binding to PAMPs or DAMPs, PRRs rapidly initiate intracellular signaling pathways (such as the NF-κB, IRF, and inflammasome pathways). This triggers the production of inflammatory factors, chemokines, and type I interferons, thereby initiating inflammatory responses to eliminate pathogens or repair damage. PRRs represent the body's first line of defense against infection, and the rapidity and broad specificity of their response are crucial for host survival. However, aberrant activation of PRR signaling is also a cause of many chronic inflammatory diseases, autoimmune disorders, and neurodegenerative diseases. Therefore, precisely regulating PRR activity has become a key therapeutic strategy for these conditions.
MCE has cataloged 338 inhibitors targeting key PRRs, such as NLRs, TLRs, C-type Lectin Receptors (CLRs), and cGAS, to support drug discovery efforts for chronic inflammatory diseases.
Cat. No.: HY-182797
CAS No.: 3117340-01-6
Target:
Research Areas:
NHWL071065 is a CRBN-targeting IKZF1/IKZF3 molecular glues degrader. NHWL071065 selectively degrades IKZF1 and IKZF3 in lymphoma cells via the ubiquitin-proteasome pathway. NHWL071065 inhibits the proliferation of lymphoma cells. NHWL071065 downregulates proteins involved in cytoskeleton assembly, cell adhesion and immune regulation in cells, while upregulating proteins related to the type I IFN signaling pathway. NHWL071065 can be used in the research of lymphoma .
Cat. No.: HY-P992369
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
